MedTrace Logo

AIH Risk Stratification With Multiparametric MRI

NCT04339621 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 11

Last updated 2023-11-22

No results posted yet for this study

Summary

The primary aim of this study is to investigate whether the baseline cT1 can predict those whose condition relapses following treatment withdrawal.

The secondary aim is to investigate correlation of cT1 with histology to explore utility as a monitoring tool.

A total of 97 patients with AIH will be recruited and divided into 2 arms. 20 of which will be treatment naive and the other 77 will have been on treatment for the past 18-24 months and will be coming in for therapy cessation review.

Conditions

  • Autoimmune Hepatitis

Interventions

DEVICE

LiverMultiscan

The LiverMultiscan is a quick 15 minute, contrast free MRI scan that provides three metrics on liver health namely fat, iron and fibro-inflammatory scores

Sponsors & Collaborators

  • Perspectum

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-20
Primary Completion
2021-09-08
Completion
2023-04-15
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04339621 on ClinicalTrials.gov